PAVM · PAVmed Inc.
$2.79
+0.10 (+3.72%)
At close · Oct 9
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the accompanying unaudited condensed consolidated financial statements are issued.”View the 10-Q filed Aug 13, 2026
Market Cap
$21.51M
Shares
8.00M
Volume · Oct 9
12.15K
Avg daily vol (3M)
30.07K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.69
Open$2.76
Day$2.66–2.76
52W close$2.66–16.65
Avg vol 30d28K
Short int13K · 0.2% float · 1.0d
Short vol46%
Last earningsAug 14, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Nov 13, 2026
Est · unconfirmed
· in 5 wks
filed Aug 13, 2026
call held Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$112,000
Trailing 12 months
Net income (TTM)
−$12.09M
Trailing 12 months
Revenue growth YoY
+450.0%
Year over year
Operating margin
-23,841.1%
Trailing 12 months
P / E (TTM)
2.6
Trailing earnings · reciprocal yield 38.7%
FCF yield
-35.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$3.78M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+940.0%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
0.2%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−62%
below
Price vs 50-day avg
−39%
below
RSI (14)
27
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−37%
trailing
6-month return
−71%
trailing
YTD return
−59%
this year
Relative strength
−79%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $7 — 200d above 50d
Institutional flow
Flat
1 of 19 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.16% of float · ▲ +16.7% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
19 holders — near 3-yr low, contrarian setup
Squeeze score
30
low risk · 0–100
Fundamentals
Revenue growth
+20%
Y/Y
Gross margin
-3%
EPS growth
−138%
Y/Y
Free cash flow
$-5.2M
Quant / Vol
risk profile
Volatility
135%
annualized · 1-yr
Max drawdown
−84%
past year
ATR
13.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Nov 4, 2021
Gross margins
· At moderate volumes
90%
Margins
· At moderate volumes
at least 90%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−62%
Bearish
Price vs 50-day avg
−39%
Bearish
RSI (14)
27
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $4 › 200d $7 — 200d above 50d
Institutional flow
Flat
1 of 19 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.16% of float · ▲ +16.7% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
19 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $3
Now $3 · 0%
Range high $17
vs 200-day avg -62%
vs 50-day avg -39%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PAVM
this stock
PAVmed Inc.
|
$21.51M | — | +20.0% | — | 0.2% |
|
ABT
Abbott Laboratories
|
$171.55B | -21.4% | +5.7% | 27.6 | 0.8% |
|
MDT
Medtronic plc
|
$112.24B | -8.7% | +8.4% | 21.6 | 3.1% |
|
SYK
Stryker Corp
|
$106.24B | -21.2% | +11.2% | 28.7 | 1.5% |
|
BSX
Boston Scientific Corp
|
$61.07B | -55.9% | +12.5% | 17.1 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PAVM | -0.4% | -37.0% | -70.5% | -27.1% | -59.4% |
| SPY | +1.3% | +2.1% | +9.0% | +1.5% | +13.5% |
| vs SPY | -1.7% | -39.1% | -79.5% | -28.6% | -72.9% |